RCS - Oxford BioDynamics - OBD in New Report on NHS Prostate Cancer Screening

Oxford BiodynamicsAnnouncement

14/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251014:nRSN1784Da&default-theme=true

RNS Number : 1784D  Oxford BioDynamics PLC  14 October 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or "OBD" or the "Company")

 

Prostate Cancer Research NHS screening report highlights OBD's EpiSwitch PSE

 

·      Report concludes that a targeted prostate cancer UK screening
programme is currently feasible

·      Emerging technologies, including EpiSwitch PSE, should be
considered in the NHS

·      PSE recognised for its strong potential to cut false positives
and minimise diagnostic procedures

 

Oxford, UK - 14 October 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics platform, notes the
publication today of "Prostate Cancer Screening: The Impact on the NHS," a
new report by prominent UK charity Prostate Cancer Research (PCR)(1).

 

The report concludes that targeted prostate cancer screening in the UK is
practical, and that the UK National Screening Committee (NSC) should recommend
a national programme for screening prostate cancer in high-risk men aged
45-69.

 

Furthermore, the report makes the case that new screening technologies, such
as the EpiSwitch PSE (https://www.94percent.com/) blood test from Oxford
BioDynamics, should be considered in the NHS as they promise greater accuracy,
fewer unnecessary procedures, and can form the foundation for a
population-wide programme. EpiSwitch PSE is named in the report, highlighting
its strong potential to reduce false positives and minimise the need for
further diagnostic procedures in low-risk cases.

 

The publication includes modelling for a future screening programme, which
shows that adopting a reflex test with a balanced high specificity and
sensitivity could reduce anticipated demand on MRI by more than 86% and
biopsy procedures by 84%, while also saving costs for the NHS.

 

Iain Ross, Executive Chariman of Oxford BioDynamics, said:

 

"We welcome the conclusions of this timely report, which demonstrates that the
technologies and systems are now in place to make prostate cancer screening
both feasible and effective to reduce inequalities and save lives.

 

"The findings recognise that our EpiSwitch PSE blood test, with its
unmatched 97% specificity, could significantly reduce unnecessary MRIs and
biopsies, and therefore help to make large-scale screening a practical reality
for the NHS. This is consistent with the real-world data recently published
showing PSE can enable clinics to safely avoid biopsies in up to 79% of
patients with an elevated PSA(2)."

 

The report will be presented this afternoon at Prostate Cancer Research's
Parliamentary Reception in the House of Commons. The event is sponsored by
Calvin Bailey MBE MP, Rt Hon David Lammy FRSA MP, and former prime minister Rt
Hon Rishi Sunak MP.

 

-Ends-

 

References

(1 ) Prostate Cancer Research. Prostate Cancer Screening: The Impact on the
NHS. Evaluating the demand, costs and delivery of a national prostate cancer
screening programme in the UK. October 2025.
https://www.prostate-cancer-research.org.uk
(https://www.prostate-cancer-research.org.uk)

(2) Berghausen, J. et al. (2025). EpiSwitch PSE Blood Test Reduces Unnecessary
Prostate Biopsies: A Real-World Clinical Utility Study. Cancers.
https://doi.org/10.3390/cancers17132193
(https://doi.org/10.3390/cancers17132193)

 

For further information please contact:

 Oxford BioDynamics Plc                       +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Camarco - Financial PR

 Marc Cohen / Tilly Butcher / Fergus Young    +44 (0)20 3757 4980

                                              OBDFinancial@camarco.co.uk (mailto:OBDFinancial@camarco.co.uk)

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com/) ,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPGPPUUPAGQW



            Copyright 2019 Regulatory News Service, all rights reserved